---
title: "Asarfi Hospital Ltd (543943) — Share Price, Financials & Analysis"
symbol: "543943"
company: "Asarfi Hospital Ltd"
canonical: "https://tapetide.com/stocks/543943"
isin: "INE0DN001027"
nse_symbol: "ASARFIHOSPITALLTD"
bse_code: "543943"
sector: "Healthcare Services"
industry: "Hospitals"
market_cap_cr: 383.73
generated_at: "2026-09-13T19:09:01.795Z"
---

# Asarfi Hospital Ltd (543943)

Canonical page: https://tapetide.com/stocks/543943

## Company

- **NSE Symbol:** ASARFIHOSPITALLTD
- **BSE Code:** 543943
- **ISIN:** INE0DN001027
- **Sector:** Healthcare Services
- **Industry:** Hospitals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2023-07-26
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** asarfi.in

## About

Incorporated in 2005, Asarfi Hospital Ltd 
 provides primary health services & treatment 
 and specialized super speciality health service[1]

## Latest Price

## Key Fundamentals

Observed at 2026-09-11T04:45:45.048995Z.

- **Market Cap:** ₹383.73 Cr
- **Classification:** SME
- **P/E (reported):** 22
- **EPS (TTM):** ₹9.22
- **EPS (reported):** ₹2.11
- **Book Value:** ₹51.79
- **Price to Book:** 3.84
- **Dividend Yield:** 0%
- **ROE:** 13.06%
- **ROCE:** 14.97%
- **Debt to Equity:** 0.59
- **Revenue (yearly):** ₹173.5 Cr
- **Net Income:** ₹16.31 Cr
- **EBITDA:** ₹35.27 Cr
- **52-Week High:** ₹256.95
- **52-Week Low:** ₹123
- **RSI (14):** 43.41

## Tapetide Score

- **Score:** 62 / 100
- **Score date:** 2026-09-04
- **Archetype:** Priced for Perfection
- **What it means:** The business scores well but the multiple leaves little room for error. The debate here is about the price, not the company; small disappointments tend to cost more at rich valuations.
- **Pillar profile:** Quality: Good · Valuation: Expensive · Momentum: Rising
- **Percentile:** 92.5 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 44.01 | 9% |
| growth | 83.3 | 9% |
| momentum | 68.78 | 12% |
| ownership | 59.51 | 24% |
| quality | 69.85 | 22% |
| valuation | 46.11 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is expected to give good quarter
- Company has delivered good profit growth of 37.1% CAGR over last 5 years
- Company's working capital requirements have reduced from 24.3 days to 19.2 days

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -116.69% | -121.56% | — |
| ebitda margin growth | 19.05% | -17.48% | -2.86% | — |
| net income growth | 10.26% | 53.87% | 29% | 37% |
| revenue growth | 4.79% | 35.44% | 36% | 26% |
| roce | 22.64% | 83.68% | 83.68% | — |
| roe | 8.93% | 120.98% | 9.49% | — |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 20.05 | 24.04 | 30.86 | 32.89 | 35.1 | 35.66 | 44.85 | 46.06 | 45.03 | 47.34 |
| Expenses | 16.04 | 20.05 | 24.06 | 25.9 | 28.64 | 28.63 | 35.94 | 35.95 | 37.17 | 37.92 |
| Operating Profit | 4.01 | 3.99 | 6.8 | 6.99 | 6.46 | 7.03 | 8.91 | 10.11 | 7.86 | 9.42 |
| OPM % | 20 | 16.6 | 22.03 | 21.25 | 18.4 | 19.71 | 19.87 | 21.95 | 17.46 | 19.9 |
| Other Income | 1.2 | -0.41 | 1.13 | 0.89 | 3.66 | 1.42 | 0.8 | 1.5 | 0.67 | 0.59 |
| Interest | 0.6 | 0.76 | 0.76 | 1.18 | 1.35 | 1.22 | 1.07 | 1.25 | 0.71 | 1.17 |
| Depreciation | 3.25 | 3.49 | 3.18 | 3.04 | 3.23 | 2.96 | 2.88 | 2.86 | 2.74 | 3.13 |
| Profit before tax | 1.36 | -0.67 | 3.99 | 3.66 | 5.54 | 4.27 | 5.76 | 7.5 | 5.08 | 5.71 |
| Tax % | 102.94 | -76.12 | 27.07 | 25.41 | 30.87 | 25.29 | 25.17 | 27.07 | 19.49 | 25.22 |
| Net Profit | -0.05 | -0.16 | 2.9 | 2.72 | 3.83 | 3.2 | 4.3 | 5.48 | 4.09 | 4.27 |
| EPS in Rs | -0.03 | -0.08 | 1.47 | 1.38 | 1.95 | 1.63 | 2.19 | 2.78 | 2.08 | 2.17 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 43 | 54 | 65 | 69 | 81 | 116 | 173 | 183 |
| Expenses | 37 | 46 | 54 | 55 | 65 | 93 | 138 | 147 |
| Operating Profit | 6 | 8 | 11 | 14 | 16 | 24 | 36 | 36 |
| OPM % | 15 | 15 | 17 | 20 | 20 | 20 | 20 | 20 |
| Other Income | 0 | 0 | 1 | 2 | 2 | 8 | 3 | 4 |
| Interest | 1 | 1 | 1 | 1 | 3 | 4 | 4 | 4 |
| Depreciation | 2 | 3 | 3 | 4 | 9 | 13 | 11 | 12 |
| Profit before tax | 4 | 5 | 8 | 11 | 6 | 15 | 23 | 24 |
| Tax % | 27 | 26 | 26 | 26 | 33 | 25 | 24 | — |
| Net Profit | 3 | 4 | 6 | 8 | 4 | 11 | 17 | 18 |
| EPS in Rs | 21.48 | 28.83 | 46.79 | 5.53 | 2.14 | 5.58 | 8.68 | 9.22 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 1 | 1 | 1 | 14 | 20 | 20 | 20 |
| Reserves | 12 | 16 | 21 | 27 | 51 | 62 | 79 |
| Borrowings | 5 | 7 | 12 | 17 | 32 | 49 | 58 |
| Other Liabilities | 9 | 13 | 28 | 34 | 52 | 34 | 38 |
| Total Liabilities | 28 | 37 | 63 | 93 | 154 | 164 | 194 |
| Fixed Assets | 18 | 22 | 31 | 39 | 94 | 101 | 108 |
| CWIP | 0 | 2 | 9 | 18 | 0 | 2 | 2 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 9 | 13 | 22 | 37 | 60 | 61 | 84 |
| Total Assets | 28 | 37 | 63 | 93 | 154 | 164 | 194 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 2 | 10 | 9 | 7 | 26 | -4 | 19 |
| Cash from Investing Activity | -5 | -16 | -23 | -21 | -63 | -8 | -19 |
| Cash from Financing Activity | 2 | 6 | 14 | 15 | 36 | 13 | 5 |
| Net Cash Flow | 0 | 0 | 0 | 1 | -1 | 1 | 5 |
| Free Cash Flow | -5 | 2 | -10 | -13 | -20 | -14 | 1 |
| CFO/OP | 62 | 142 | 104 | 73 | 162 | -3 | 69 |

### Ratios

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 20 | 14 | 30 | 90 | 109 | 125 | 114 |
| Inventory Days | 23 | 13 | 16 | 26 | 32 | 30 | 30 |
| Days Payable | 156 | 23 | 34 | 91 | 445 | 171 | 156 |
| Cash Conversion Cycle | -113 | 5 | 11 | 25 | -304 | -16 | -12 |
| Working Capital Days | -10 | -38 | -36 | 18 | 3 | 50 | 19 |
| ROCE % | — | 25 | 29 | 26 | 11 | 16 | 19 |

## Shareholding Pattern

### Quarterly

| Category | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 83.03% | 61.17% | 61.17% | 61.17% | 61.17% | 61.17% | 61.17% | 61.17% | 61.17% | 61.17% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0.1% | 0.05% | 0% | 0% | 0% |
| DIIs | 0% | 3.25% | 2.33% | 1.95% | 2.92% | 3.18% | 2.19% | 1.98% | 2.4% | 2.97% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 0% | 27.4% | 31.63% | 32.99% | 30.86% | 29.89% | 30.89% | 31.72% | 30.63% | 30.1% |
| Others | 16.97% | 8.18% | 4.87% | 3.89% | 5.05% | 5.66% | 5.7% | 5.13% | 5.79% | 5.76% |
| No. of Shareholders | 37 | 706 | 1261 | 1284 | 1262 | 1176 | 1167 | 1225 | 1316 | 1399 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 1 / 6 / 12

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 198.4 | Sell |
| EMA (10) | 199.35 | Sell |
| SMA (20) | 211.48 | Sell |
| EMA (20) | 206 | Sell |
| SMA (50) | 214.57 | Sell |
| EMA (50) | 211.69 | Sell |
| SMA (100) | 214.93 | Sell |
| EMA (100) | 208.64 | Sell |
| SMA (200) | 197.61 | Sell |
| EMA (200) | 193.77 | Sell |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 39.31 | Neutral |
| MACD (12,26,9) | -7.3 | Sell |
| Stochastic (14,3,3) | 35.18 | Neutral |
| ADX (14) | 26.7 | Buy |
| Williams %R (14) | -74.14 | Neutral |
| ATR (14) | 10.71 | High Volatility |
| ROC (12) | -13.93 | Sell |
| Stoch RSI (14) | 44.12 | Neutral |
| UO (7,14,28) | 44.58 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-05 | [Intimation Of Appointment Of Cost Auditor - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations. 2015.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1e41f95d-42c3-4de2-9bef-9a8c0f023e7b.pdf) |
| 2026-09-05 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ab0c143d-263f-4199-a32e-708fe4e87c5d.pdf) |
| 2026-08-25 | [Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) 2015.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2179d6b8-0433-4584-b011-52a1ac61656f.pdf) |
| 2026-08-18 | [Board Meeting Intimation for Notice Of 21St Annual General Meeting Of Asarfi Hospital Limited.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ef67f97e-d022-4b6f-9d1e-0c59251d0440.pdf) |
| 2026-08-08 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1cd90cec-e194-4bd9-b966-0adecb4b8b12.pdf) |
| 2026-08-07 | [Board Meeting Outcome for Submission Of Unaudited Standalone And Consolidated Financial Results For The Quarter Ended 30 June 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=71ba9cc5-4b1f-4cc1-8c41-99a62fdc9751.pdf) |
| 2026-08-07 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9c0d5f3a-803b-46a8-a242-677d7f4fca59.pdf) |
| 2026-08-04 | [Board Meeting Intimation for The Unaudited Financial Results Of The Company For The Quarter Ended 30Th June 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=22ca4e48-0280-4f0f-98a9-6bacdeaabb82.pdf) |
| 2026-07-27 | [Outcome Of Analyst / Investor Webinar Held On 24 July 2026 Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3d05d736-ae52-44f9-a0d2-be869341ab90.pdf) |
| 2026-07-16 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3a9bb198-7ef6-478e-bf77-e1b52c33613c.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-07 | [Submission Of Unaudited Standalone And Consolidated Financial Results For The Quarter Ended 30 June 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=12401408-0579-43be-bdb8-8d813a96f059.pdf) |
| 2026-05-11 | [Submission Of Standalone & Consolidated Audited Financial Results For The Quarter And Year Ended 31St March 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=27123881-60c1-4238-ac85-636ea84fc934.pdf) |
| 2026-02-09 | [Submission Of Unaudited Financial Results For The Quarter Ended 31St December 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c49f6d67-efa8-4b15-a213-cb81fc7aafa9.pdf) |
| 2025-11-12 | [Submission Of Standalone & Consolidated Unaudited Financial Results For The Half Year Ended September 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fbace95b-e958-4f27-8f0b-cf609b0c963a.pdf) |
| 2025-11-10 | [Submission Of Standalone & Consolidated Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=76a14c1c-e252-4433-b524-4f4e593f1593.pdf) |
| 2025-08-07 | [Financial Result For Quarter Ended 30Th June2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6e5288ba-26a1-409e-a034-da27fb276592.pdf) |
| 2025-01-31 | [Outcome Of Board Meeting Held On 31St January 2025 And Submission Of Unaudited Financial Results For The Quarter Ended 31St December 2024 As Per SEBI (Listing Obligations And Disclosure Requirements)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=32ca711b-7cf2-4b51-af7a-e44d63719cdf.pdf) |
| 2024-10-30 | [Outcome Of Board Meeting Held On 30Th October, 2024 And Submission Of Unaudited Financial Results For The Half Year Ended 30Th September, 2024 As Per SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=87342313-d9f2-4921-817d-231d871287f2.pdf) |
| 2024-07-04 | [Disclosure Of The Impact Of Audit Qualifications On Asarfi Hospital Limited Standalone & Consolidated Financial Statements.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0f47da11-baf6-4068-a118-6381ff12073f.pdf) |
| 2024-06-13 | [IMPACT ON AUDIT QUALIFICATION FOR THE YEAR ENDED 31 MARCH, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=66495770-4422-4b6f-adb8-a3118456367b.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-08-07 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=eac06530-f7e1-4893-8bf6-1c056f9cef2c.pdf) |
| 2026-05-11 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=99cce2ca-808d-4785-8088-42a5a6138224.pdf) |
| 2026-02-09 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b2f1fe25-51d9-4f05-b602-0e02036618ef.pdf) |
| 2025-11-10 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6745a814-3fea-4b31-91c2-41d42a7bf6d2.pdf) |
| 2025-08-07 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7f47328d-75e5-47be-916d-0ff003cf06e8.pdf) |
| 2025-05-09 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7b3cfc4e-5680-4402-b127-805eba4f9e7a.pdf) |
| 2025-01-31 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7dc9df0a-3ab2-4157-b0d5-79aaf59cba45.pdf) |
| 2024-10-30 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3713065d-b52a-4150-b9ec-ec91b5a83a6c.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-05-30 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f8ba789b-f8f4-41f7-aac9-1da56f284cc6.pdf) |
| 2025-11-22 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=61cd9443-064e-4032-ac4a-12a7f4daec1a.pdf) |
| 2025-05-14 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e9bec89f-9e1e-4da5-84f6-8f6206887ec4.pdf) |
| 2024-11-09 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a60f7c61-13dd-4930-a175-8e2e931d443a.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9h - Board approved FY26 audited standalone and consolidated results; auditors issued unmodified opinion. | [Submission Of Standalone & Consolidated Audited Financial Results For The Quarter And Year Ended 31St March, 2026 9h - Board approved FY26 audited standalone and consolidated results; auditors issued unmodified opinion.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/27123881-60c1-4238-ac85-636ea84fc934.pdf) |
| 9h - Board approved audited standalone and consolidated FY26 results on 11 May 2026; auditors issued unmodified opinion. | [Board Meeting Outcome for Outcome Of Board Meeting Held On 11Th May, 2026 And Submission Of Standalone & Consolidated Audited Financial Results For The Quarter And Year Ended 31St March, 2026 Pursuant To Regulation 33 Of SEBI (LODR) Regulations, 2015 9h - Board approved audited standalone and consolidated FY26 results on 11 May 2026; auditors issued unmodified opinion.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/519e3943-dfa6-435a-aa36-df8a99333960.pdf) |
| 9 Feb - Unaudited Q3 results for quarter ended 31-Dec-2025; standalone PAT Rs1,298.34 lakhs; unmodified review. | [Board Meeting Outcome for Outcome Of Board Meeting Held On 09 February 2026 And Submission Of Unaudited Financial Results For The Quarter Ended 31St December 2025. 9 Feb - Unaudited Q3 results for quarter ended 31-Dec-2025; standalone PAT Rs1,298.34 lakhs; unmodified review.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/056fad93-3a7b-4d18-931e-61d3eb150ba8.pdf) |
| 9 Feb - Q3 FY26 results: revenue ₹46.10 Cr, PAT ₹5.42 Cr; nine-month revenue ₹126.67 Cr, PAT ₹12.74 Cr, announced Feb 9, 2026. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 9 Feb - Q3 FY26 results: revenue ₹46.10 Cr, PAT ₹5.42 Cr; nine-month revenue ₹126.67 Cr, PAT ₹12.74 Cr, announced Feb 9, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/58b1e423-66ee-40da-9974-13d8e8ead7c5.pdf) |
| 9 Feb - Investor Presentation of the Company for the quarter ended December 31,2025. | [Announcement under Regulation 30 (LODR)-Investor Presentation 9 Feb - Investor Presentation of the Company for the quarter ended December 31,2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b2f1fe25-51d9-4f05-b602-0e02036618ef.pdf) |
| 8h - Investor Presentation of Asarfi Hospital Limited for the Quarter and Financial Year ended 31st March, 2026. | [Announcement under Regulation 30 (LODR)-Investor Presentation 8h - Investor Presentation of Asarfi Hospital Limited for the Quarter and Financial Year ended 31st March, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/99cce2ca-808d-4785-8088-42a5a6138224.pdf) |
| 8h - Asarfi Hospital published audited Q4 and FY26 standalone and consolidated results on 11 May 2026. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 8h - Asarfi Hospital published audited Q4 and FY26 standalone and consolidated results on 11 May 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/4faf095f-5340-4aca-a0df-1dc72390cada.pdf) |
| 4 May - Board meeting on 11 May 2026 to approve FY2026 audited financial results; trading window closed 1-31 April 2026. | [Board Meeting Intimation for Intimation Under Regulation 29(1)(A) Of SEBI (LODR) Regulations, 2015 4 May - Board meeting on 11 May 2026 to approve FY2026 audited financial results; trading window closed 1-31 April 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3fd3c4c3-0a41-47a5-9281-4e41a08a558b.pdf) |
| 4 May - Board meeting on 11 May 2026 to approve FY2026 audited financial results; trading window closed 1-31 April 2026. | [Board Meeting Intimation for Intimation Under Regulation 29(1)(A) Of SEBI (LODR) Regulations, 2015 4 May - Board meeting on 11 May 2026 to approve FY2026 audited financial results; trading window closed 1-31 April 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/3fd3c4c3-0a41-47a5-9281-4e41a08a558b.pdf) |
| 27 Mar - Trading window closed from April 01, 2026 until 48 hours after audited FY2026 results. | [Closure of Trading Window 27 Mar - Trading window closed from April 01, 2026 until 48 hours after audited FY2026 results.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/867816c5-7c16-485a-adc4-249411b9c7d7.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Sep 2020 | [Concall - Sep 2020](https://www.bseindia.com/xml-data/corpfiling/AttachHis/72a2b1f6-8b53-442f-804e-4e9a361cd20f.pdf) |
| Oct 2015 | [Concall - Oct 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4370368A_51DF_478D_A859_C6F9BED4B3E1_105435.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/61cd9443-064e-4032-ac4a-12a7f4daec1a.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e9c32da0-d53d-4b19-86bc-ccebe668df7a.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a60f7c61-13dd-4930-a175-8e2e931d443a.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/616b64e7-1754-4794-bd68-68b5f1fdabd4.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c868bd1b-461f-459d-9cff-2b54b67d215d.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6598f2b2-d772-47b2-b3f6-38b4a3b324ff.pdf) |
| Nov 2021 | [Concall - Nov 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/65c52ab8-6e5b-4f5c-8272-9631b0af92dc.pdf) |
| Nov 2020 | [Concall - Nov 2020](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d0bc1269-6369-4429-8bdd-0b51222311d9.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Financial Year 2013 from nse](https://archives.nseindia.com/annual_reports/AR_1915_RICOAUTO_2012_2013_20092013133536.zip) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/fd8fd703-44a2-4bc6-aae0-879b89d76707.pdf) |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f1646e90-cb6d-48a4-954b-8ebfdb725742.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/01f8e741-bfa2-4359-a10d-54527fc49ed8.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5b4a13b9-f698-4227-ab81-9ce3199ea748.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4bbaa194-0e07-4200-850e-27cb7760b1bd.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1c629e61-e2cd-48b1-8cd9-a02328165d65.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/520008/77161520008.pdf) |
| from bse | [Financial Year 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/520008/72348520008_25_09_21.pdf) |
| from bse | [Financial Year 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/520008/67382520008.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:09:01.795Z.